Advanced Multiparametric MRI for decoding smoldering Multiple Sclerosis LesionsCollege of Medicine, Tanta University, Egypt
Courtesy of Rania Essameldein Mohamed Ali, Hossam A Zytoon, Ashraf Ali Aboelsafa



Multiple sclerosis (MS) is an autoimmune demyelinating, chronic inflammatory, and neurodegenerative disease of the central nervous system (CNS) with damage to the myelin. It is considered a non-traumatic physically debilitating neurological disorder that is associated with great morbidity, despite the broad therapeutic landscape, often leading to significant handicap and great repercussions in daily life (1). Patients with MS show a wide range of symptoms, with variable disease course and prognosis. Multiple sclerosis is a journey from being at risk, through the asymptomatic, prodromal, and symptomatic phases of the disease. It is suspected when a person presents with sensory, visual, motor symptoms, balance issues, and fatigue, particularly if these symptoms are fluctuating or come and go. It is also important to consider MS if these symptoms occur in separate areas of the CNS and at different points in time. This can be mono- or poly-symptomatic depending on the location of the eloquent lesion (s) (2).

For years, the progression of MS was thought to be associated with the appearance of new lesions on consecutive MRI studies, but it is now becoming clear that a chronic inflammatory state with quiescent lesions contributes to the functional deterioration of the patients. This chronic inflammatory state, together with focal inflammatory lesions and brain atrophy, can explain why patients continue to deteriorate neurologically without any new T2 hyperintense lesions appearing on MRI (3, 4).

Secondary Progressive Multiple Sclerosis (SPMS) represents a challenging phase of MS, marked by gradual neurological decline and reduced inflammatory activity. In recent years, advanced MRI techniques are crucial in understanding and monitoring MS, especially regarding smoldering lesions. Smoldering lesions, also known as chronic active lesions or slowly expanding lesions, are a type of lesion found in MS that exhibit a distinct dark rim on MRI scans, indicating ongoing inflammation. These lesions differ from typical MS lesions as they slowly grow and expand into the surrounding normal-appearing white matter (NAWM), suggesting a persistent inflammatory process (5).

Conventional MRI techniques such as T2-weighted and FLAIR sequences provide insight into lesion burden but often fail to distinguish between active, chronic active, and inactive lesions. Chronic active (smoldering) lesions marked by a rim of persistent microglial activity are of clinical significance due to their association with long-term disability (4). Advanced MRI techniques, including susceptibility-weighted imaging (SWI), arterial spin labelling (ASL), Diffusion tensor imaging (DTI), and tractography, offer non-invasive insights into lesion composition, perfusion, microstructural integrity, and connectivity (1,2,3).

By providing this case of relapsing-remitting MS, we aimed to highlight the pivotal role of multiparametric MRI with advanced quantitative MRI techniques such as SWI, ASL, DTI and tractography in the characterization of MS lesions with identification of early cerebral structural and perfusion changes occurring during the course of the disease, particularly smoldering MS lesions, with assessment of the disease progression and evaluation of the treatment response.


Multiparametric MRI, provides a robust framework for the detection and characterization of chronic active MS lesions (smoldering lesions). These imaging techniques offer complementary insights into lesion biology, allowing for improved disease monitoring, risk stratification, and treatment planning. As demonstrated in this case, such a multimodal approach may reveal clinically silent yet biologically active lesions, highlighting the importance of expanding MRI protocols in MS management. Additionally, the integrating SWI with quantitative susceptibility map, pseudo-continuous ASL, as well as DTI and tractography into clinical practice, particularly in patients with stable MS who present with subtle cognitive decline or other non-relapsing symptoms, could improve the follow up of the disease progression and support earlier therapeutic intervention to mitigate disability.